Perrigo (NYSE:PRGO – Free Report) had its price objective lifted by Canaccord Genuity Group from $17.00 to $19.00 in a research note issued to investors on Friday,Benzinga reports. They currently have a buy rating on the stock.
A number of other research firms also recently weighed in on PRGO. Wall Street Zen downgraded Perrigo from a “buy” rating to a “hold” rating in a research note on Saturday. Weiss Ratings upgraded shares of Perrigo from a “sell (d-)” rating to a “sell (d)” rating in a research note on Thursday, August 6th. Finally, Zacks Research downgraded Perrigo from a “hold” rating to a “strong sell” rating in a research note on Thursday. One equities research analyst has rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Reduce” and a consensus target price of $18.50.
Perrigo Stock Performance
NYSE:PRGO opened at $15.78 on Friday. Perrigo has a 1 year low of $9.23 and a 1 year high of $21.01. The stock has a market capitalization of $2.19 billion, a P/E ratio of -1.26, a price-to-earnings-growth ratio of 1.82 and a beta of 0.71. The company has a current ratio of 2.32, a quick ratio of 1.32 and a debt-to-equity ratio of 1.31. The firm has a 50 day moving average of $14.83 and a 200-day moving average of $12.48.
Perrigo (NYSE:PRGO – Get Free Report) last announced its earnings results on Wednesday, August 5th. The company reported $0.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.39 by $0.11. The company had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.02 billion. Perrigo had a negative net margin of 41.85% and a positive return on equity of 11.25%. Perrigo’s quarterly revenue was down 3.1% on a year-over-year basis. During the same period in the prior year, the business earned ($0.06) earnings per share. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. As a group, sell-side analysts anticipate that Perrigo will post 2.17 EPS for the current fiscal year.
Perrigo Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 15th. Stockholders of record on Friday, November 27th will be given a $0.29 dividend. This represents a $1.16 dividend on an annualized basis and a dividend yield of 7.4%. The ex-dividend date is Friday, November 27th. Perrigo’s payout ratio is presently -9.27%.
Institutional Investors Weigh In On Perrigo
Large investors have recently added to or reduced their stakes in the stock. Bank of America Corp DE lifted its position in Perrigo by 25.5% during the first quarter. Bank of America Corp DE now owns 1,568,598 shares of the company’s stock worth $16,847,000 after purchasing an additional 318,248 shares during the period. Gamco Investors INC. ET AL increased its holdings in Perrigo by 29.7% in the 1st quarter. Gamco Investors INC. ET AL now owns 1,397,866 shares of the company’s stock valued at $15,013,000 after buying an additional 320,081 shares during the period. Diamond Hill Capital Management LLC Investment Advisor acquired a new position in shares of Perrigo in the 2nd quarter valued at approximately $4,066,000. Empowered Funds LLC raised its position in shares of Perrigo by 41.6% in the 1st quarter. Empowered Funds LLC now owns 511,872 shares of the company’s stock valued at $5,498,000 after buying an additional 150,438 shares in the last quarter. Finally, Gabelli Funds LLC lifted its holdings in shares of Perrigo by 29.8% during the 1st quarter. Gabelli Funds LLC now owns 893,359 shares of the company’s stock worth $9,595,000 after acquiring an additional 205,311 shares during the period. Institutional investors and hedge funds own 95.91% of the company’s stock.
Perrigo Company Profile
Perrigo Company plc is a global consumer self-care company that develops, manufactures and markets over-the-counter health products, wellness products and personal care items. Its portfolio includes products for allergy, pain relief, digestive health, skin care, smoking cessation, women’s health and other everyday health needs, along with vitamins, nutritional supplements and infant nutrition products.
Perrigo supplies products under its own brands, acquired brands and retailer-owned private-label labels.
Read More
- Five stocks we like better than Perrigo
- SK hynix Says Memory Demand Beats Supply Through 2030—What It Means for Micron and SanDisk
- STMicroelectronics Could Reach New Highs—Here’s What Needs to Happen
- Marvell Eyes a Swing for the AI Networking Fences as Markets Weigh Lumentum Price Tag
- Exxon’s Refining Profits Soared—Did Chevron Get the Same Windfall?
Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with MarketBeat.com's FREE daily email newsletter.
